Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.

Source:http://linkedlifedata.com/resource/pubmed/id/16477567

Clin. Infect. Dis. 2006 Mar 15 42 6 870-7

Download in:

View as

Triples

General Info

PMID
16477567